What Analysts Are Saying About GE HealthCare Techs Stock
Portfolio Pulse from Benzinga Insights
GE HealthCare Techs (NASDAQ:GEHC) received mixed analyst ratings with a majority being bullish. The average 12-month price target is $99.78, marking a 13.88% increase from the previous target. Analysts from firms like Mizuho, Evercore ISI Group, Citigroup, Argus Research, HSBC, Morgan Stanley, and UBS have adjusted their ratings and price targets, reflecting various market conditions and company performance. GE HealthCare Techs, a leader in medical technology and diagnostics, shows solid revenue growth but faces challenges in net margin, ROA, and debt management.
May 01, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GE HealthCare Techs received mixed but mostly bullish analyst ratings, with an updated average 12-month price target of $99.78, indicating a positive outlook. The company's financial performance shows strong revenue growth but challenges in profitability and debt management.
The positive adjustment in price targets by analysts from reputable firms suggests a bullish outlook for GEHC, despite some financial challenges. The increase in the average price target reflects confidence in the company's growth potential, likely to influence investor sentiment positively in the short term. However, concerns about net margin, ROA, and debt management could temper gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100